Browse > Article
http://dx.doi.org/10.5483/BMBRep.2015.48.9.258

Growth hormone-releasing peptide-biotin conjugate stimulates myocytes differentiation through insulin-like growth factor-1 and collagen type I  

Lim, Chae Jin (Department of Microbiology and Molecular Biology, School of Bioscience and Biotechnology, Chungnam National University)
Jeon, Jung Eun (CRID Center, NeoPharm Co., Ltd.)
Jeong, Se Kyoo (CRID Center, NeoPharm Co., Ltd.)
Yoon, Seok Jeong (Peptide R&D Center, Incospharm Corporation)
Kwon, Seon Deok (Peptide R&D Center, Incospharm Corporation)
Lim, Jina (Peptide R&D Center, Incospharm Corporation)
Park, Keedon (Peptide R&D Center, Incospharm Corporation)
Kim, Dae Yong (Department of Pharmaceutical Science and Engineering, Seowon University)
Ahn, Jeong Keun (Department of Microbiology and Molecular Biology, School of Bioscience and Biotechnology, Chungnam National University)
Kim, Bong-Woo (Department of Cosmetic Science & Technology, Seowon University)
Publication Information
BMB Reports / v.48, no.9, 2015 , pp. 501-506 More about this Journal
Abstract
Based on the potential beneficial effects of growth hormone releasing peptide (GHRP)-6 on muscle functions, a newly synthesized GHRP-6-biotin conjugate was tested on cultured myoblast cells. Increased expression of myogenic marker proteins was observed in GHRP-6-biotin conjugate-treated cells. Additionally, increased expression levels of insulin-like growth factor-1 and collagen type I were observed. Furthermore, GHRP-6-biotin conjugate-treated cells showed increased metabolic activity, as indicated by increased concentrations of energy metabolites, such as ATP and lactate, and increased enzymatic activity of lactate dehydrogenase and creatine kinase. Finally, binding protein analysis suggested few candidate proteins, including desmin, actin, and zinc finger protein 691 as potential targets for GHRP6-biotin conjugate action. These results suggest that the newly synthesized GHRP-6-biotin conjugate has myogenic stimulating activity through, at least in part, by stimulating collagen type I synthesis and several key proteins. Practical applications of the GHRP-6-biotin conjugate could include improving muscle condition. [BMB Reports 2015; 48(9): 501-506]
Keywords
Biotin; Collagen; Growth-hormone releasing peptide; Insulin-like growth factor; Myogenesis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Paulin D and Li Z (2004) Desmin: a major intermediate filament protein essential for the structural integrity and function of muscle. Exp Cell Res 301, 1-7   DOI
2 Li Z, Mericskay M, Agbulut O et al (1997) Desmin is essential for the tensile strength and integrity of myofibrils but not for myogenic commitment, differentiation, and fusion of skeletal muscle. J Cell Biol 139, 129-144   DOI
3 Li H, Choudhary SK, Milner DJ, Munir MI, Kuisk IR and Capetanaki Y (1994) Inhibition of desmin expression blocks myoblast fusion and interferes with the myogenic regulators MyoD and myogenin. J Cell Biol 124, 827-841   DOI
4 Lokireddy S, Wijesoma IW, Sze SK, McFarlane C, Kambadur R and Sharma M (2012) Identification of atrogin-1-targeted proteins during the myostatin-induced skeletal muscle wasting. Am J Physiol Cell Physiol 303, C512-529   DOI
5 Cohen S, Zhai B, Gygi SP and Goldberg AL (2012) Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy. J Cell Biol 198, 575-589   DOI
6 Hong J, Kim BW, Choo HJ et al (2014) Mitochondrial complex I deficiency enhances skeletal myogenesis but impairs insulin signaling through SIRT1 inactivation. J Biol Chem 289, 20012-20025   DOI
7 Kim BW, Lee JW, Choo HJ et al (2010) Mitochondrial oxidative phosphorylation system is recruited to detergent-resistant lipid rafts during myogenesis. Proteomics 10, 2498-2515   DOI
8 Asakura A, Komaki M and Rudnicki M (2001) Muscle satellite cells are multipotential stem cells that exhibit myogenic, osteogenic, and adipogenic differentiation. Differentiation 68, 245-253   DOI
9 Florini JR, Ewton DZ and Magri KA (1991) Hormones, growth factors, and myogenic differentiation. Annu Rev Physiol 53, 201-216   DOI
10 Lee CS, Yi JS, Jung SY et al (2010) TRIM72 negatively regulates myogenesis via targeting insulin receptor substrate-1. Cell Death Differ 17, 1254-1265   DOI
11 Frago LM, Paneda C, Dickson SL, Hewson AK, Argente J and Chowen JA (2002) Growth hormone (GH) and GH-re- leasing peptide-6 increase brain insulin-like growth factor-I expression and activate intracellular signaling pathways involved in neuroprotection. Endocrinology 143, 4113-4122   DOI
12 Frago LM, Paneda C, Argente J and Chowen JA (2005) Growth hormone-releasing peptide-6 increases insulinlike growth factor-I mRNA levels and activates Akt in RCA-6 cells as a model of neuropeptide Y neurones. J Neuroendocrinol 17, 701-710   DOI
13 Zhou S, Salisbury J, Preedy VR and Emery PW (2013) Increased collagen synthesis rate during wound healing in muscle. PLoS One 8, e58324   DOI
14 Bonaldo P, Braghetta P, Zanetti M, Piccolo S, Volpin D and Bressan GM (1998) Collagen VI deficiency induces early onset myopathy in the mouse: an animal model for Bethlem myopathy. Hum Mol Genet 7, 2135-2140   DOI
15 Takano H, Komuro I, Oka T et al (1998) The Rho family G proteins play a critical role in muscle differentiation. Mol Cell Biol 18, 1580-1589   DOI
16 Schwander M, Leu M, Stumm M et al (2003) Beta1 integrins regulate myoblast fusion and sarcomere assembly. Dev Cell 4, 673-685   DOI
17 Granado M, Garcia-Caceres C, Tuda M, Frago LM, Chowen JA and Argente J (2011) Insulin and growth hormone-releasing peptide-6 (GHRP-6) have differential beneficial effects on cell turnover in the pituitary, hypothalamus and cerebellum of streptozotocin (STZ)-induced diabetic rats. Mol Cell Endocrinol 337, 101-113   DOI
18 Yi JS, Park JS, Ham YM et al (2013) MG53-induced IRS-1 ubiquitination negatively regulates skeletal myogenesis and insulin signalling. Nat Commun 4, 2354   DOI
19 Paneda C, Arroba AI, Frago LM et al (2003) Growth hormone-releasing peptide-6 inhibits cerebellar cell death in aged rats. Neuroreport 14, 1633-1635   DOI
20 Smith RG (2005) Development of growth hormone secretagogues. Endocr Rev 26, 346-360   DOI
21 Berlanga J, Cibrian D, Guevara L et al (2007) Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction. Clin Sci (Lond) 112, 241-250   DOI
22 Pontiroli AE (1998) Peptide hormones: Review of current and emerging uses by nasal delivery. Adv Drug Deliv Rev 29, 81-87   DOI
23 Fleisher D, Niemiec SM, Oh CK, Hu Z, Ramachandran C and Weiner N (1995) Topical delivery of growth hormone releasing peptide using liposomal systems: an in vitro study using hairless mouse skin. Life Sci 57, 1293-1297   DOI
24 Charge SB and Rudnicki MA (2004) Cellular and molecular regulation of muscle regeneration. Physiol Rev 84, 209-238   DOI
25 Smith CK, 2nd, Janney MJ and Allen RE (1994) Temporal expression of myogenic regulatory genes during activation, proliferation, and differentiation of rat skeletal muscle satellite cells. J Cell Physiol 159, 379-385   DOI
26 Micic D, Casabiell X, Gualillo O, Pombo M, Dieguez C and Casanueva FF (1999) Growth hormone secretagogues: the clinical future. Horm Res 51 Suppl 3, 29-33   DOI
27 Makrantonaki E, Schonknecht P, Hossini AM et al (2010) Skin and brain age together: The role of hormones in the ageing process. Exp Gerontol 45, 801-813   DOI
28 Zouboulis CC and Makrantonaki E (2012) Hormonal therapy of intrinsic aging. Rejuvenation Res 15, 302-312   DOI
29 DeVita RJ (1997) Small molecule mimetics of GHRP-6. Expert Opin Investig Drugs 6, 1839-1843   DOI
30 Makrantonaki E, Zouboulis CC and German National Genome Research N (2007) The skin as a mirror of the aging process in the human organism--state of the art and results of the aging research in the German National Genome Research Network 2 (NGFN-2). Exp Gerontol 42, 879-886   DOI
31 Florini JR, Ewton DZ and Coolican SA (1996) Growth hormone and the insulin-like growth factor system in myogenesis. Endocr Rev 17, 481-517